SUNNYVALE, Calif., May 19, 2020 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) today announced that MedTech
Breakthrough, an independent market intelligence organization that
recognizes the top companies, technologies and products in the
global health and medical technology market, has selected the
Accuray Synchrony® Real-time Adaptive Technology for the
Radixact® System as the winner of its "Best Overall
Medical Device Solution" award in the fourth annual MedTech
Breakthrough Awards program.
The Radixact® System, the next-generation
TomoTherapy® platform, is a radiotherapy system designed
to provide oncology clinical teams with the imaging capabilities,
treatment flexibility and precise dose delivery they had come to
expect with its predecessor device, with the addition of components
that can significantly enhance interoperability and increase
patient throughput.
Originally developed to expand on the Accuray
CyberKnife® System's unique automatic motion tracking
and synchronization capabilities, Synchrony for the Radixact System
is designed to adapt for tumors that move as a result of bodily
processes, including respiration and digestion, as well as patient
movement. Some tumors may be located in areas of the body that move
regularly, such as the lungs. Also, filling of the bladder, gas in
the bowel or even slight patient movements can shift the tumor
target by a millimeter or more.
Tracking tumor movement — and synchronizing precise treatment
delivery with that movement using the Accuray Synchrony Real-time
Adaptive Technology — helps to maximize treatment effectiveness and
minimize dose to surrounding tissues. The beams of radiation are
delivered continuously throughout the treatment session as the
patient breathes naturally. In comparison, gating methods deliver
radiation only when the tumor is close to the expected location and
pause treatment delivery when the moving tumor is outside of the
"treatment window." This lengthens the time the patient needs to be
on the treatment table.
"Cancer is increasingly being managed as a chronic condition.
With this will be a corresponding rise in the use of radiation
therapy, and a need for technology that can precisely and
accurately treat each patient's unique tumor," said Joshua H. Levine, president and CEO at Accuray.
"Our one-of-a-kind, artificial-intelligence driven Synchrony
software combined with the Radixact System delivers a breakthrough
in precision radiation therapy treatments. Synchrony is the only
technology that uses image guidance to automatically adapt and
synchronize the radiation beam to the position of the tumor if and
when it moves during treatment. When used with the Radixact
System, it facilitates the efficient and effective delivery of both
hypofractionated and standard radiation therapy, making it easier
for clinical teams to provide treatments tailored to meet each
individual patient's needs."
The mission of the MedTech Breakthrough Awards is to honor
excellence and recognize the innovation, hard work and success in a
range of health and medical technology categories, including
Robotics, Clinical Administration, Telehealth, Patient Engagement,
Electronic Health Records (EHR), mHealth, Medical Devices, Medical
Data and many more. This year's program attracted more than 3,750
nominations from over 15 different countries throughout the
world.
"The Synchrony® Real-time Adaptive Technology for the
Radixact® System embodies the spirit of the MedTech
Breakthrough Awards program by delivering a true breakthrough for
cancer patients and the clinicians who treat them," said
James Johnson, managing director,
MedTech Breakthrough. "Accuray has developed a powerful portfolio
of advanced technology solutions that is revolutionizing radiation
therapies for patients, minimizing the amount of healthy tissue
exposed to high-dose radiation and, ultimately, helping to improve
patient outcomes. We are thrilled to award Accuray with the marquee
"Best Overall Medical Device Solution" designation for their
breakthrough technology that is strengthening and advancing the
toolkit for cancer-fighting solutions. Congratulations to the
entire Accuray team on their well-deserved industry recognition
with this 2020 MedTech Breakthrough award."
About Accuray
Accuray Incorporated (Nasdaq: ARAY)
develops, manufactures and sells radiotherapy systems that are
intended to make cancer treatments shorter, safer, personalized and
more effective, ultimately enabling patients to live longer, better
lives. Our radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and
recognition platform for global technology innovation and
leadership, the MedTech Breakthrough Awards program is an
independent program devoted to honoring excellence in medical and
health related technology companies, products, services and people.
The MedTech Breakthrough Awards provide a platform for public
recognition around the achievements of breakthrough health and
medical companies and products in categories that include Patient
Engagement, mHealth, Health & Fitness, Clinical Administration,
Healthcare IoT, Medical Data, Healthcare Cybersecurity and more.
For more information visit MedTechBreakthrough.com.
Media Contacts
Beth
Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-synchrony-real-time-adaptive-technology-for-the-radixact-system-wins-2020-medtech-breakthrough-award-301061452.html
SOURCE Accuray Incorporated